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Abstract
Background: Patients with congenital diaphragmatic hernia (CDH) have structural and functional different
pulmonary vessels, leading to pulmonary hypertension. They often fail to respond to standard vasodilator therapy
targeting the major vasoactive pathways, causing a high morbidity and mortality. We analyzed whether the
expression of crucial members of these vasoactive pathways could explain the lack of responsiveness to therapy in
CDH patients.
Methods: The expression of direct targets of current vasodilator therapy in the endothelin and prostacyclin
pathway was analyzed in human lung specimens of control and CDH patients.
Results: CDH lungs showed increased expression of both ETA and ETB endothelin receptors and the rate-limiting
Endothelin Converting Enzyme (ECE-1), and a decreased expression of the prostaglandin-I2 receptor (PTGIR). These
data were supported by increased expression of both endothelin receptors and ECE-1, endothelial nitric oxide
synthase and PTGIR in the well-established nitrofen-CDH rodent model.
Conclusions: Together, these data demonstrate aberrant expression of targeted receptors in the endothelin and
prostacyclin pathway in CDH already early during development. The analysis of this unique patient material may
explain why a significant number of patients do not respond to vasodilator therapy. This knowledge could have
important implications for the choice of drugs and the design of future clinical trials internationally.
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Background
Pulmonary hypertension (PH) is the leading cause of
morbidity and mortality in patients with congenital dia-
phragmatic hernia (CDH) [1]. The altered development
of the pulmonary vasculature and the disordered pul-
monary vascular remodeling [2] in combination with the
imbalance of vasoactive mediators caused by endothelial
dysfunction result in the arrest of pulmonary vascular
growth in these patients. Current treatment of CDH
patients is not evidence based [3] and is derived from
studies in adults, leading mainly to off-label and
unlicensed use of drugs. Current knowledge is based on
compassionate use and case reports, while some patients
with CDH were included in trials that were underpow-
ered for definitive conclusions. Even international
therapy guidelines are based on consensus only (level 3
evidence) [4]. In 2012, experts evaluated the current
antenatal and postnatal management of CDH and em-
phasized the importance of optimal management of PH
in these patients [5]. Worldwide, PH treatment is mainly
directed against the receptors of the endothelin (ET)
and prostacyclin (PGI2) pathways or the conversion of
cyclic guanosine monophosphate (cGMP) in the nitric
oxide (NO) pathway (Fig. 1a). In spite of these targeted
treatments, it is still largely unknown how the different
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Fig. 1 Three major pathways involved in vasodilation and vasoconstriction. a Schematic overview of the major pathways and the key proteins
involved in vasodilation and vasoconstriction. b Aberrant expression of key factors in the three pathways in both human and rat congenital
diaphragmatic hernia (CDH). Solid arrows represent up- or downregulation in human CDH, dashed arrows represent up- or downregulation in rat
CDH. ECE-1 = endothelin converting enzyme 1, ETA = endothelin A, ETB = endothelin B, eNOS = endothelial nitric oxide synthase, sGC = soluble
guanylate cyclase, COX = cyclooxygenase, PGIS = prostaglandin synthase, PGI2 = prostaglandin I2, AC = adenylate cyclase, TBXAS1 = thromboxane
synthase, TXA2 = thromboxane
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components of these pathways are expressed in lungs of
unaffected individuals and CDH patients.
Previous studies reported increased levels of both the
endothelin A (ETA) and B (ETB) receptors in human
CDH as well as in the nitrofen rat model [6, 7].
Endothelin-1 (ET-1) is a potent vasoconstrictor [8] and
is increased in lung tissue of patients with pulmonary
hypertension. Moreover, high plasma levels of circulating
ET-1 associated with the severity of PH in human CDH
[9]. NO reduces the affinity of the ETA receptor for ET-
1 and may therefore terminate the ET-1 mediated signal-
ing [10]. NO is synthesized by different NO synthases
(NOS): endothelial NOS (eNOS), inducible NOS (iNOS)
and neuronal NOS (nNOS), which are all expressed in
the lung. However, only eNOS and, to some extent,
iNOS, are expressed in the pulmonary vasculature and
modulate pulmonary vascular tone [11, 12]. Some
human and rat CDH studies showed a decrease in eNOS
[13, 14]. However, we and others showed either no dif-
ferences, or even an increased expression of eNOS in
both human and rat CDH [15–19]. PGI2 is an important
mediator of vasodilation, acting through the
prostaglandin-I2 receptor (PTGIR) [20]. Several prosta-
cyclin receptor agonists have been used in the treatment
of persistent pulmonary hypertension of the newborn
with variable effects [21–23]. Limited data are available
about the use of these drugs in patients with CDH, but
the few available case reports show contrasting results
[24–26]. An overview of the current data for human and
the rat model is provided (Tables 1 and 2).
Since CDH patients respond poorly to current treat-
ment strategies, we hypothesized that these effects might
be due to an aberrant expression of important vasoactive
factors. Here, we are the first to analyze the expression
of the direct targets of the most commonly used vaso-
dilator drugs, as well as some of the important members
of the three major vasoactive pathways. Using unique
patient lung material, we show an increased expression
of both endothelin receptors and the rate-limiting
endothelin converting enzyme (ECE-1), as well as a
decreased expression of the prostaglandin-I2 receptor in
human CDH. Moreover, we found changes in the
expression of these and other important factors of the
pathways in rat CDH (Fig. 1b).
Methods
Human lung samples
Human lung samples were retrieved from the archives
of the Department of Pathology of the Erasmus Medical
Center, Rotterdam. In our high-volume, leading center
of the EURO consortium [4], approximately 15 to 20
CDH patients a year are born, which ensures a large
experience in the treatment of this disease. Paraffin-
embedded lung samples, lacking severe hemorrhage or
necrosis, were selected of controls, of CDH patients and
of patients with lung hypoplasia or pulmonary hyperten-
sion unrelated to CDH. Only lung material of patients
with a severe left-sided CDH and a survival of less than
7 h were selected to prevent secondary sequelae. Patient
characteristics are described in Table 3.
Animal model
The well-established animal model was used, where in
short pregnant Sprague-Dawley rats received either
100 mg nitrofen dissolved in 1 ml olive oil or just 1 ml
olive oil by gavage on gestational age day E9.5 [27].
Nitrofen induces left-sided CDH in approximately 70%
of the offspring, while all pups have pulmonary
hypertension. At day E21 pups were delivered by caesar-
ean section and euthanized by lethal injection of
pentobarbital.
Table 1 Overview of studies in human CDH
Our group Others
Increased expression of ETA
and ETB (protein level)
- Increased ET-1 (plasma levels and protein
level) -[43]
Increased expression of
ECE-1 (protein level)
- Increased ET-1 (plasma levels) [9]
- Increased expression of ETA and ETB
(RNA and protein level) [6]
No differences in eNOS
expression [16]
- Increased expression of eNOS in arteriolar
endothelium and alveolar epithelium
(protein level) [17]
- No differences in eNOS expression
(protein level) [19]
- Decreased expression of eNOS (protein
and RNA level) [14]
Decreased expression of
Ptgir (protein level)
- No information about prostaglandin I2
Table 2 Overview of studies in experimental rat CDH
Our group Others
Increased expression of ETA
(RNA and protein level) and
ETB (RNA level)
- Increased expression of ETA and
ETB (RNA and protein level) [7]
Increased expression of ECE-1
(RNA level)
- Increased expression of ET-1 after
1 and 6 h of ventilation (RNA
level) [18]
- Increased response of arterioles to
ET-1 [44]
Increased expression of eNOS
(RNA and protein level)
- Increased expression of eNOS
(RNA and protein level) [15]
- Increased expression of eNOS after
1 h of ventilation (RNA level) [18]
- Decreased expression of eNOS
(RNA and protein level) [13]
Increased expression of Ptgir (RNA
level) and decreased expression of
Tbxas1 (RNA level)
- Increased levels of prostaglandin I2
and an increased ratio of
prostaglandin I2 and thromboxane
(protein level) [34]
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Immunohistochemistry staining
Immunohistochemistry (IHC) was performed on 5 μm
thick paraffin sections of lungs of both rats and
humans according to standard protocols, using the
Envision™ detection system (Dako Cytomatic,
Glostrup, Denmark) [28]. Briefly, sections were
deparaffinized with xylene and rehydrated in gradual
series of ethanol, after which antigen retrieval was
performed by boiling samples in 10 mM Tris
(pH 9.0), 1 mM EDTA. Primary and Horse Redox
Peroxidase conjugated secondary antibodies were
diluted in antibody dilution buffer (DAKO) with 0,5%
Tween-20, and the peroxidase was detected with
diamino-benzidine tetrahydrochloride (Fluka, Buchs,
Switzerland). Validated primary antibodies used for
IHC were Endothelin receptor A (ETA; 1:5000 (rat)
1:100 (human); Alamone, Jerusalem, Israel), Endothe-
lin receptor B (ETB; 1:2500 (rat) 1:500 (human);
Alamone), Endothelin Converting Enzyme (ECE-1;
1:500 (human); Abcam, Cambridge, MA, USA),
endothelial nitric oxide synthase (eNOS; 1:400 (rat);
Thermo Fisher Scientific, Waltham, MA, USA) and
prostaglandin-I2 receptor (Ptgir; 1:1000 (rat) 1:500
(human); Cayman Chemical, Ann Arbor, Michigan,
USA). Negative controls were performed by omitting
the primary antibody.
Quantitative real-time polymerase chain reaction (qPCR)
RNA isolation of whole lungs of rat pups, cDNA synthe-
sis and subsequent qPCR analysis was performed as pre-
viously described [28]. The gene-specific primers used
are listed in Table 4. Actb was used as reference gene.
Statistical analyses
Data are presented as means (SD) for normally
distributed variables. Univariate analyses were performed
using independent samples t-tests for normally distrib-
uted variables. The analyses were performed using SPSS
21.0 for Windows (Armonk, NY, USA: IBM Corp.). All
statistical tests were two-sided and used a significance
level of 0.05.
Results
We analyzed the expression of receptors which are tar-
geted during treatment, as well as other critical factors
of the different vasoactive pathways, in order to unravel
the unresponsiveness of CDH patients to current vaso-
dilator therapies. Therefore, a unique set of lung mater-
ial of CDH patients was used and the data were verified
using the more dynamical nitrofen rat model.
Human
Besides the use of inhaled NO (iNO), current treatment
is based on targeting the receptors in both the prosta-
cyclin and endothelin pathway. Therefore, we analyzed
the expression of the critical proteins of both pathways
in human lung samples of control and CDH patients by
immunohistochemistry. Human control lung samples
showed little expression of the main target of the prosta-
cyclin therapy, the important prostacyclin receptor
PTGIR, in the fetal period. This sharply increased later
during gestation at the preterm and term age. However
this significant increase was absent in CDH (Fig. 2). The
ETA receptor, which induces vasoconstriction and cell
proliferation, was expressed in the small (25–50 μm)
Table 3 Patient characteristics
Disease GA Sex Age of death Cause of death
Control 18 + 0 Male – Abortion
24 + 6 Female Minutes Prematurity
26 + 5 Female 1 h Prematurity
33 + 0 Male Minutes Developmental delay
38 + 3 Male Minutes Asphyxia
38 + 5 Male 1.5 h Anencephaly
40 + 0 Female 18 h Asphyxia
CDH 17 + 6 Male – Abortion
21 + 4 Male – Abortion
36 + 2 Male Some hours Respiratory failure
36 + 2 Female Some hours Respiratory failure
37 + 2 Male 7 h Respiratory failure
38 + 0 Male 2 h Respiratory failure
40 + 0 Female Some hours Respiratory failure
LH 22 + 3 Male – Abortion
28 + 5 Female 15 min Respiratory failure
41 + 0 Male 30 min Respiratory failure
PH 34 + 3 Female 4 days PPHN
37 + 1 Male 4 days Respiratory failure
GA gestational age (weeks + days), CDH congenital diaphragmatic hernia, LH
lung hypoplasia, PH pulmonary hypertension, PPHN persistent pulmonary
hypertension of the newborn
Table 4 Primer sequences
Gene Sequence (forward 5′- 3′) Sequence (reverse 5′- 3′)
Eta AACCTGGCAACCATGAACTC ATGAGGCTTTTGGACTGGTG
Etb CAGGATTCTGAAGCTCACCCTTT TCCAAAACCAGCAAAAAACTCA
Et-1 TGTGCTCACCAAAAAGACAAGAA GGTACTTTGGGCTCGGAGTTC
Ece-1 GCAAGAACATAGCCAGCGAG CTCCGAGTATCTTCATCCATCC
eNos CATACTTGAGGATGTGGCTG CCACGTTAATTTCCACTGCT
Sma TGACCCAGATTATGTTTGAGAC AGAGTCCAGCACAATACCAG
Ptgis CATCAAACAGTTTGTGGTCCT CAAAGCCATATCTGCTAAGGT
Ptgir CACGAGAGGATGAAGTTTACCA AATCCTCTGATCGTGAGAGGC
Tbxas1 AGACTCAGGTTCCACTTCAG TCACACCTGCCTTCTATGTC
Tbxa2r ACTGTGAGGTGGAGATGATGG CAGGATGAAGACCAGCAAGG
Actb AGATGACCCAGATCATGTTTGAG GTACGACCAGAGGCATACAG
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and larger (>50 μm) vessels as well as in the very small
capillaries (<25 μm) in CDH. In contrast, the distribu-
tion of the ETA receptor in control lungs was limited to
the small and larger vessels only (Arrowheads in Fig. 3a).
The ETB receptor, involved in vasodilation through the
release of NO and PGI2 (Fig. 1), was expressed both in
the bronchial epithelium and in some of the larger ves-
sels (>50 μm) in CDH (Arrowheads in Fig. 3a). However,
the expression of ETB in control lungs was found only
in the bronchial epithelium (Fig. 3a). Next, we analyzed
the expression of ECE-1, a membrane-bound metallo-
protease that converts big-endothelin into the
biologically active compound ET1 and it is a rate-
limiting factor in the ET pathway. Early during gestation,
in the fetal period, ECE-1 is minimally expressed in the
vessels of the human control lung samples, with an
increase at preterm and term age. Increased expression
of this enzyme at both fetal, preterm and term age was
observed in CDH (Fig. 3b), indicating a potential
increased bio-availability of active ET-1 already at the
fetal stage of development.
To exclude that the differences in expression patterns of
the crucial prostacyclin – and endothelin receptors and
the rate-limiting factor ECE-1 was solely an effect of lung
hypoplasia (LH) or PH, we performed immunohistochem-
istry on lungs of patients with LH and PH with other
cause than CDH. The PTGIR receptor expression was
reduced in both LH and PH (Fig. 4a). Increased expression
of ETA was detected in the smallest vessels in lungs of
both LH and PH (Arrowheads in Fig. 4b), whereas
increased expression of ETB was only observed in both
small and very small vessels of lungs of PH patients
(Arrowheads in Fig. 4c). ECE-1 was not expressed differ-
ently in both LH and PH lung samples (Fig. 4d).
Rat
In order to validate these interesting human data, we
evaluated the expression patterns of the proteins of these
three pathways in the nitrofen rat model. This was sup-
plemented with RNA and protein expression analysis of
related factors. Real-time qPCR showed that the mRNA
expression of both the Eta and Etb receptors was signifi-
cantly higher in lungs of E21 pups with CDH compared
to those of control pups. We also analyzed the expres-
sion of the ETA and ETB ligand, Et-1, but no significant
differences were found between the groups. However,
the mRNA encoding the rate-limiting factor Ece-1 was
significantly increased in CDH compared to control,
confirming the human data (Fig. 5a). Next, we analyzed
the protein expression pattern of the ET receptors with
immunohistochemistry. The ETA receptor was
expressed in the small capillaries of both groups at E15
until E21 with a stronger expression level in CDH. At
E21 only CDH lungs showed expression of the ETA
receptor in the larger vessels (>50 μm) (Fig. 5b). The
ETB receptor was expressed in the bronchial epithelium
of all lungs without significant differences between con-
trol and CDH at all ages (Fig. 5c). There was a signifi-
cant higher mRNA expression of eNos in CDH rats
compared to control in relation to all cells as well as in
relation to only the smooth muscles cells (Fig. 6a) or
endothelial cells (data not shown). This increased
expression was clearly detectable with immunostaining
in the larger and smaller (<50 μm) vessels at E21. How-
ever, no obvious differences were noted earlier during
development (E15 till E19) (Fig. 6b). Although there was
no difference in expression of prostaglandin-I2 synthase
(Ptgis) between control and CDH rat pups, there was a
slight increase in the expression of Ptgir and the
Fig. 2 Suppressed progression of prostaglandin-I2 receptors during gestation in human CDH. Representative images show progressive expression
of PTGIR in the vessels during gestation in human control lungs, which is reduced in lungs of human CDH patients. Scale bars represent 20 μm.
Patients: GA 18 + 0, 33 + 0 and 38 + 0 (control), GA 21 + 4, 36 + 2 and 37 + 2 (CDH)
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prostaglandin-E1 receptor (Ptger1) in CDH at the mRNA
level in both the whole lung as well as compared to the
number of smooth muscle cells. In contrast, the expres-
sion of thromboxane synthase (Tbxas1), the enzyme
converting prostaglandin H2 into thromboxane A2,
which is in turn critical for vasoconstriction, was clearly
reduced in CDH, whereas the thromboxane receptor
(Tbxa2r) did not show significant differences (Fig. 7a).
However, immunostaining showed no clear differences
in expression of PTGIR in the vessels between both
groups (Arrowheads in Fig. 7b).
Discussion
This is the first combined study showing the aberrant
expression of different important factors in the endothe-
lin, NO and PGI2 pathways in CDH patients (Fig. 1b)
and human patients with LH or PH unrelated to CDH,
possibly explaining why a large number of patients do
Fig. 3 Increased expression of ECE-1 and both ET receptors in human CDH. a Representative images show increased expression of ETA in the
smaller vessels and clear expression of the ETB receptor in vessels in lungs of CDH patients compared to control. b ECE-1 is increasingly expressed
in the vessels in human control patients during gestation, whereas the expression is already high in the fetal stage of development in CDH
patients. Arrows indicate vessels, A indicates airways. Scale bars represent 100 μm (low power) and 20 μm (high power). Patients: GA 38 + 3
(control), GA 38 + 0 and 37 + 2 (CDH) (A + B). Patients: GA 18 + 0, 26 + 5 and 38 + 0 (control), GA 21 + 4, 36 + 2 and 37 + 2 (CDH) (C + D)
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not respond to the current vasodilator therapy. We
focused our research on direct targets of the most fre-
quent used drugs to investigate the effectiveness of the
current approach and combined this with the analysis of
some key factors of the different pathways.
Since our unique human CDH material is scarce
and a limiting factor, since only specimens of new-
borns who lived for a short period were analyzed to
prevent secondary morphological changes, supplemen-
tal analyses were done on lung tissue of the nitrofen
rat model.
In line with previous studies in both human and rat,
we found a significant increased expression of the ETA
and ETB receptor, important targets of vasodilator
therapy, in human CDH patients and the rat model [6,
7, 29]. However, we are the first to show an increased
expression of the crucial ECE-1 enzyme in both human
pulmonary vessels of CDH patients and whole lung
homogenates of nitrofen treated rat pups. ECE-1
converts big ET-1 into the active form of ET-1 and is
the rate-limiting step in the production of ET-1 [30].
Although there was no apparent difference in total ET-1
Fig. 4 Expression of prostaglandin and endothelin factors in human LH and PH patients. Representative images show expression of PTGIR (a),
ETA (b), ETB (c) and ECE-1 (d) in patients with lung hypoplasia (LH) or pulmonary hypertension (PH) unrelated to CDH. The expression of ETA is
increased in the smaller vessels of patients with LH and PH (b), and the expression of ETB is only increased in the vessels of patients with PH (c).
ECE-1 is not differently expressed in the vessels both LH and PH lung samples (d)Scale bars represent 20 μm. Arrows indicate very small vessels.
Patients: GA 38 + 3 (control), GA 41 + 0 (LH), GA 34 + 3 (PH)
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in CDH pups, the higher expression of ECE-1 in lungs
of CDH pups may lead to an increase in the active form
of ET-1.
Previously, we and others showed no apparent differ-
ences in the NO pathway [16, 19]. In contrast to other
studies [13, 14, 19, 29], we found an increased expres-
sion of eNOS in CDH rats in this study. This may be
explained by the decreased NO availability, or by the
process of eNOS uncoupling. In case of decreased bio-
availability of the cofactor tetrahydrobiopterin (BH4),
eNOS produces superoxide instead of NO [31]. This
superoxide leads to oxidative stress, which has been
observed in vessels of patients with PH [32]. The
enhanced activation of the ETA receptor, as mentioned
before, might lead to the increase in superoxide produc-
tion through the induction of reactive oxygen species
(ROS) and can thereby induce SMC proliferation and
vasoconstriction. Thus, eNOS uncoupling leads to a
reduction in NO bioavailability without a necessary
change in the amount of eNOS [31]. Furthermore, we
Fig. 5 Upregulation of ET-receptors in lungs of rat CDH. a Relative expression of the ETA receptor (Eta) and ETB receptor (Etb) shows a significant
increase in rat CDH pups (p < 0.001 and p < 0.05, respectively), whereas RNA expression of ET-1 shows no differences between control and CDH
and Ece-1 is significantly increased (p < 0.05). b Representative images show increased expression of the Eta receptor in the parenchyma of CDH
lungs at all stages of development and in the larger vessels at E21. c Representative images show expression of the Etb receptor in the bronchial
epithelium of both control and CDH lungs at all stages of development. Inserts represent higher magnifications of a pulmonary vessel. *p < 0.05,
***p < 0.001. Error bars represent SD. Arrows indicate vessels, A indicates airways. Scale bars represent 100 μm (low power) and 20 μm
(high power)
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Fig. 6 Increased eNOS expression in lungs of CDH rats. a eNOS expression compared to total rat lungs (left) or to the pulmonary Sma+ smooth
muscle cells fraction (right) shows increased expression in CDH lungs. b Representative images show increased expression of eNOS in the vessels
of the lungs of CDH rat pups at E21, but not at other stages of gestation. **p < 0.01, ***p < 0.001. Error bars represent SD. Arrows indicate
vessels, A indicates airways. Scale bars represent 100 μm (low power) and 20 μm (high power) and 50 μm
Fig. 7 Prostacyclin expression in rat pups. a Relative gene expression of prostaglandin I synthase (Ptgis), thromboxane synthase (Tbxas1),
prostaglandin-I2 receptor (Ptgir) and prostaglandin-E1 receptor (Ptger1) in lungs of control and CDH rat pups. b Representative images showing
the protein expression of PTGIR in the pulmonary vessels in control and CDH lungs.**p < 0.01, ***p < 0.001. Error bars represent SD. Arrows
indicate vessels, A indicates airways. Scale bars represent 100 μm (low power) and 20 μm (high power)
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have shown a slight increase in expression of the cGMP-
specific phosphodiesterase 5 (Pde5) in the NO pathway
in nitrofen treated rat pups previously. However, no
differences were found in its phosphorylation or its
downstream targets, protein kinase G1 (Prkg1) and
Prkg2 [27].
The increased expression of PTGIR in control lungs
during gestation could result from the gradual increase
of placental PGI2 toward term [33]. The decreased
expression in CDH may be a sign of reduced activation
of this pathway. In contrast to our human results, we
found no differences in the expression of Ptgir in CDH
rat pups and an increase of this receptor on mRNA
level. Since PGI2 is a potent vasodilator and thromb-
oxane A2 (TXA2) a potent vasoconstrictor, the increased
expression of Ptgir and decreased expression of Tbxas1
was unexpected. However, this aberrant balance between
PGI2 and TXA2 in CDH was already previously
described by our group [34]. We showed an increased
level of 6-keto-PGF1α, the stable metabolite of PGI2, and
an increased ratio of 6-keto-PGF1α and TXA2 in both
lung homogenates and broncho-alveolar lavage (BAL)
fluid of nitrofen treated rat pups. The discrepancy be-
tween the increased mRNA expression of Ptgir in CDH
lungs and the absence of differences at the protein level
is most likely caused by the difference in sensitivity
between qPCRs and IHC. Furthermore, the different
results in human and rat could be explained by the fact
that we only used the most severe cases of human CDH
where the rat model covers all cases.
Current treatment of CDH patients with PH is not evi-
dence based [3] and most patients respond poorly to the
used medication. Inhaled NO (iNO) is most commonly
used as a first line drug, but its use varies significantly
among different centers internationally [35]. In contrast
to the promising results of iNO in patients with persist-
ent pulmonary hypertension of the newborn [36], studies
in CDH have failed to show its efficacy [35, 37], as no
trials have been performed to evaluate the potential role
of iNO specifically in CDH patients. Apart from iNO
therapy there are some case reports on the use of silden-
afil and prostacyclins in CDH patients with variable
results [25, 26, 38, 39]. However, administration of
enteral sildenafil in neonates leads to highly variable
plasma concentrations because of variable gut absorp-
tion and/or limited hepatic clearance [40]. The recent
availability of intravenous sildenafil may change its appli-
cation [41], but solid pharmacokinetic data on optimal
dosage are still to be published. Treatment with
endothelin receptor antagonists is even a bigger problem
since these drugs are only available in oral form, while
data of its use in newborns are virtually absent concern-
ing dosage absorption and safety. The fact that the
current therapy should be considered mainly as” trial
and error” and is effective in the minority of patients
with CDH strengthens our results that there are possibly
more pathways affected. Furthermore, the severity of PH
in CDH patients has been known as an important pre-
dictor of the outcome and further evaluation of current
therapies has been recommended by experts in the field
[5]. Future treatment should become more personalized
in this group of patients using pathway directed clinical
trials and risk stratification [42].
Although the nitrofen rat model is well established,
there are still differences in embryonic maturation
between rat and human, which may have affected the
results. Furthermore, ideally, we would like to be able to
directly correlate the findings of aberrant expression of
the different vasoactive pathways with the individual
response of patients to specific vasoactive drugs.
However, given the overall limitations of these types of
studies and the lack of material of patients who did
respond to one of the three therapies, this remains
impossible as repeated lung biopsies would be needed to
accomplish this.
Conclusions
In conclusion, our study shows the aberrant expression
of specific vasodilator drug targets and crucial, rate-
limiting factors in human CDH and the nitrofen rat
model in both the endothelin, NO and PGI2 pathway
already early during development. Since PH is still a
major problem and the most important cause of morbid-
ity and mortality in CDH patients nowadays while
current treatment strategies are disappointing, a good
insight in these pathways is needed for specific and
patient directed targeting of pharmacotherapy.
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